Back to Search
Start Over
6MO PCSK9 inhibitor evolocumab reduces cardiotoxicity and inflammation induced by doxorubicin-trastuzumab sequential treatment through MyD88/NF-kB/mTORC1 pathways.
- Source :
-
Annals of Oncology . 2021 Supplement 5, Vol. 32, pS362-S362. 1p. - Publication Year :
- 2021
- Subjects :
- *CARDIOTOXICITY
*INFLAMMATION
*THERAPEUTICS
Subjects
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 32
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 152688632
- Full Text :
- https://doi.org/10.1016/j.annonc.2021.08.284